Ira Spector
Directeur Général chez SFA Therapeutics, Inc.
Profil
Ira Spector is currently the Chief Executive Officer at SFA Therapeutics, Inc. Previously, he worked as the Executive Vice President-Analytics & Consulting at ICON plc.
He completed his undergraduate degree at Washington University in St. Louis, his doctorate at the University of Medicine & Dentistry of New Jersey, and his MBA at Drexel University.
Postes actifs de Ira Spector
| Sociétés | Poste | Début |
|---|---|---|
SFA Therapeutics, Inc.
 SFA Therapeutics, Inc. Packaged SoftwareTechnology Services SFA Therapeutics, Inc. is a clinical-stage biotech company based on breakthrough research of the human microbiome licensed from Temple University. SFA Therapeutics is located in Jenkintown, PA. Ira Spector has been the CEO of the company since 2017. The company is developing a platform of safer therapeutics focused on the treatment of inflammatory diseases, targeting NF-kB and RAS. SFA has identified six small molecule drug candidates from this platform, including its lead asset, SFA-002, which has shown promising phase 1a results and is currently being investigated in a phase 1b study for psoriasis. The company's research program is focused on the intersection of chronic inflammation and cancer. | Directeur Général | 01/08/2017 |
Anciens postes connus de Ira Spector
| Sociétés | Poste | Fin |
|---|---|---|
| ICON PUBLIC LIMITED COMPANY | Corporate Officer/Principal | - |
Formation de Ira Spector
| University of Medicine & Dentistry of New Jersey | Doctorate Degree |
| Drexel University | Masters Business Admin |
| Washington University in St. Louis | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ICON PUBLIC LIMITED COMPANY | Commercial Services |
| Entreprise privées | 1 |
|---|---|
SFA Therapeutics, Inc.
SFA Therapeutics, Inc. Packaged SoftwareTechnology Services SFA Therapeutics, Inc. is a clinical-stage biotech company based on breakthrough research of the human microbiome licensed from Temple University. SFA Therapeutics is located in Jenkintown, PA. Ira Spector has been the CEO of the company since 2017. The company is developing a platform of safer therapeutics focused on the treatment of inflammatory diseases, targeting NF-kB and RAS. SFA has identified six small molecule drug candidates from this platform, including its lead asset, SFA-002, which has shown promising phase 1a results and is currently being investigated in a phase 1b study for psoriasis. The company's research program is focused on the intersection of chronic inflammation and cancer. | Technology Services |